Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 99mtc Ethyl Cysteinate Dimer
2. 99mtc Ethylcysteinate Dimer
3. 99mtc-ecd
4. Neurolite
5. Tc-99m Ecd
6. Tc-99m-bicisate
7. Tc-99m-ecd
8. Tc-99m-l,l-ecd
9. Tc-ethyl Cysteinate Dimer
10. Technetium Tc 99m Bicisate
11. Technetium Tc 99m Ethyl Cysteine Dimer
1. 14344-58-2
2. Neurolite
3. B005p07v07
4. Cysteine, N,n'-ethylenedi-, Diethyl Ester, Dihydrochloride, L-
5. L-cysteine, N,n'-1,2-ethanediylbis-, Diethyl Ester, Dihydrochloride
6. L-cysteine, N,n'-1,2-ethanediylbis-, 1,1'-diethyl Ester, Hydrochloride (1:2)
7. (2r,2'r)-diethyl 2,2'-(ethane-1,2-diylbis(azanediyl))bis(3-mercaptopropanoate) Dihydrochloride
8. Diethyl 2,2'-(ethane-1,2-diylbis(azanediyl))(2r,2'r)-bis(3-mercaptopropanoate) Dihydrochloride
9. Ethyl (2r)-2-[2-[[(1r)-2-ethoxy-2-oxo-1-(sulfanylmethyl)ethyl]amino]ethylamino]-3-sulfanyl-propanoate Dihydrochloride
10. Ecd
11. Unii-b005p07v07
12. Dtxsid4046656
13. Mfcd08061488
14. Akos017343961
15. Bicisate Dihydrochloride [who-dd]
16. Ethylene Dicysteine Diester (ecd) 2 Hcl
17. Ethylene Dicysteine Diester (ecd) Dihydrochloride
18. Q27274207
19. Diethyl (2r,2'r)-2,2'-(ethane-1,2-diyldiimino)bis(3-mercaptopropanoate) Dihydrochloride
20. Ethyl (2r)-2-[2-[[(2r)-1-ethoxy-1-oxo-3-sulfanylpropan-2-yl]amino]ethylamino]-3-sulfanylpropanoate;dihydrochloride
| Molecular Weight | 397.4 g/mol |
|---|---|
| Molecular Formula | C12H26Cl2N2O4S2 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 13 |
| Exact Mass | 396.0711050 g/mol |
| Monoisotopic Mass | 396.0711050 g/mol |
| Topological Polar Surface Area | 78.7 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 265 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Radiopharmaceuticals
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)
ABOUT THIS PAGE
A Bicisate Dihydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bicisate Dihydrochloride, including repackagers and relabelers. The FDA regulates Bicisate Dihydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bicisate Dihydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Bicisate Dihydrochloride supplier is an individual or a company that provides Bicisate Dihydrochloride active pharmaceutical ingredient (API) or Bicisate Dihydrochloride finished formulations upon request. The Bicisate Dihydrochloride suppliers may include Bicisate Dihydrochloride API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bicisate Dihydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bicisate Dihydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bicisate Dihydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bicisate Dihydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bicisate Dihydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bicisate Dihydrochloride suppliers with NDC on PharmaCompass.
Bicisate Dihydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bicisate Dihydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bicisate Dihydrochloride GMP manufacturer or Bicisate Dihydrochloride GMP API supplier for your needs.
A Bicisate Dihydrochloride CoA (Certificate of Analysis) is a formal document that attests to Bicisate Dihydrochloride's compliance with Bicisate Dihydrochloride specifications and serves as a tool for batch-level quality control.
Bicisate Dihydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Bicisate Dihydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bicisate Dihydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Bicisate Dihydrochloride EP), Bicisate Dihydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bicisate Dihydrochloride USP).
LOOKING FOR A SUPPLIER?
